Format

Send to

Choose Destination
South Asian J Cancer. 2015 Jan-Mar;4(1):15-7. doi: 10.4103/2278-330X.149931.

Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience.

Author information

1
Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
2
Department of Neurosurgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
3
Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Abstract

AIM:

To assess clinicopathological features and outcomes in patients of primary gliosarcoma with changing trends of treatment.

MATERIALS AND METHODS:

Medical records were reviewed and data collected on primary gliosarcoma over a 5-year period (2009-2013) from the departmental case files.

RESULTS:

A total 27 patients were included in this study. The median age of presentation was 54 years. There was a slight male preponderance, with male to female ratio of 1.25:1. The most common location of the tumor was temporal lobe (44.4%). Gross total resection was possible in 19 cases, near total excision was done in five cases, and only partial excision with decompression in three cases. Of the 27 patients, 80.8% patients received post-operative radical external beam radiotherapy of 60 Gy/30#/6 weeks. Concurrent and adjuvant temozolomide was used in 42.3% cases, depending on affordability and tolerance. Median overall survival was 9 months. On subgroup analysis, median overall survival in the radiotherapy plus temozolomide group was 10 months as compared to 9 months in the radiotherapy alone group; however, this was not statistically significant.(P = 0.244).

CONCLUSION:

Treating Gliosarcoma is a major therapeutic challenge for a clinician because of its poor prognosis, aggressive clinical behavior, rarity, and limited clinical experience. With surgery and concurrent chemoradiation, we were able to achieve a median overall survival of 9 months. Addition of temozolomide has shown a better trend in survival though it is not statistically significant.

KEYWORDS:

Gliosarcoma; radiotherapy; temozolomide

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center